The Pioneer: Cancer drugs exempted from custom duty

Following the exemption of customs duties on Trastuzumab Deruxtecan, Osimeritinib, and Durvalumab, in the Union Budget 2024, Mr. D. S. Negi, CEO of Rajiv Gandhi Cancer Institute lauded the government’s decision. The CEO emphasized that this move will reduce the financial burden on cancer patients, making these essential treatments more accessible and affordable. He noted that this policy shift marks a crucial step towards enhancing cancer care and supporting patients in India, as the exemption reflects a commitment to improving healthcare accessibility and reducing costs for critical treatments.